Welcome to the Emerging Strategies for Heart Failure Roundtable. Below you can download the briefing materials for this roundtable.

Introduction & Agenda

  1. Letter to Participants from Drs. Clyde Yancy and James Januzzi
  2. Emerging Strategies for Heart Failure Roundtable Agenda
  3. Interactive Table Discussion Questions

Heart Failure Guidelines

  1. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure (JACC - Yancy et al., 2016).
  2. Data Supplement: 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure (Guidelines Evidence Tables).
  3. 2013 ACCF/AHA Guideline for the Management of Heart Failure – Executive Summary (JACC - Yancy et al., 2013).
  4. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (EHJ - Ponikowski et al., 2016).

Clinical Trials

  1. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure  (PARADIGM-HF)(NEJM -  McMuray et al., 2014).
  2. Ivabradine and Outcomes in Chronic Heart Failure (SHIFT): A Randomised Placebo-controlled Study (Lancet – Swedberg, et al., 2010).

Sacubitril/Valsartan

  1. Angiotensin Receptor Neprilysin Inhibition Compared with Enalapril on the Risk of Clinical Progression in Surviving Patients with Heart Failure (Circulation - Packer, et al., 2015).
  2. Combined Neprilysin and Renin-angiotensin System Inhibition in Heart Failure with Reduced  Ejection Fraction: A Meta-analysis (EJHF – Solomon, et al., 2016).
  3. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients with Heart Failure and Reduced Ejection Fraction (JAMA Cardiol - Gaziano, et al., 2016).
  4. Effect of the Angiotensin-receptor-neprilysin Inhibitor LCZ696 Compared with Enalapril on Mode of Death in Heart Failure Patients (ESC – Desai et al., 2015).
  5. Efficacy of Sacubitril/Valsartan vs. Enalapril at Lower than Target Doses in Heart Failure with Reduced Ejection Fraction: The PARADIGM-HF Trial (EJHF – Vardeny, et al., 2016).
  6. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan (NEJM - Claggett, et al., 2015).
  7. Initiating Sacubitril/Valsartan (LCZ696) in Heart Failure: Results of TITRATION, a Double-blind, Randomized Comparison of Two Uptitration Regimens (EJHF – Senni, et al., 2016).
  8. Potential Mortality Reduction with Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure (JAMA Cardio - Fonarow, et al., 2016).

Ivabradine

  1. Chronic Exposure to Ivabradine Reduces Readmissions in the Vulnerable Phase After Hospitalization for Worsening Systolic Heart Failure: A Post-hoc Analysis of SHIFT (EJHF – Komajda, et al., 2016).
  2. Effect of Ivabradine on Recurrent Hospitalization for Worsening Heart Failure in Patients with Chronic Systolic Heart Failure: The SHIFT Study (EHJ – Borer, et al., 2012).
  3. Effects of Selective Heart Rate Reduction with Ivabradine on Left Ventricular Remodelling and Function: Results from the SHIFT Echocardiography Substudy (EHJ – Tardif, et al., 2011).
  4. Role in the Chronic Heart Failure Armamentarium (Circulation – Psotka, et al., 2016).

Prevention

  1. A Randomized Trial of Intensive versus Standard Blood-Pressure Control (NEJM - SPRINT Research Group, et al., 2015).
  2. Assessing the Risk of Progression from Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure: A Systematic Overview and Meta-Analysis. (JACC HF - Echouffo-Tcheugui, et al., 2016).
  3. Heart Failure Outcomes with Empagliflozin in Patients with Type 2 Diabetes at High Cardiovascular Risk: Results of the EMPA-REG OUTCOME® trial (EHJ – Fitchett, et al., 2016).
  4. Natriuretic Peptide-based Screening and Collaborative Care for Heart Failure: the STOP-HF Randomized Trial (JAMA – Ledwidge, et al., 2013).
  5. PONTIAC (NT-proBNP Selected Prevention of Cardiac Events in a Population of Diabetic Patients Without a History of Cardiac Disease): A Prospective Randomized Controlled Trial (JACC – Huelsmann, et al., 2013).
  6. Prevalence and Prognostic Significance of Heart Failure Stages: Application of the American College of Cardiology/American Heart Association Heart Failure Staging Criteria in the Community (Circulation – Ammar, et al., 2007).

Biomarkers/Monitors

  1. Effect of B-type Natriuretic Peptide-guided Treatment of Chronic Heart Failure on Total Mortality and Hospitalization: An Individual Patient Meta-analysis (EHJ – Troughton, et al., 2014).
  2. Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study (Circulation – Wang, et al., 2012).
  3. Pulmonary Artery Pressure-Guided Heart Failure Management Reduces 30-Day Readmissions (Circ HF – Adamson, et al., 2016).
  4. Wireless Pulmonary Artery Haemodynamic Monitoring in Chronic Heart Failure: A Randomised Controlled Trial (Lancet – Abraham, et al., 2011).

Comorbidities

  1. Noncardiac Comorbidities in Heart Failure with Reduced versus Preserved Ejection Fraction (JACC – Mentz, et al., 2014).
  2. Phenotype-Specific Treatment of Heart Failure with Preserved Ejection Fraction: A Multiorgan Roadmap (Circulation – Shah, et al., 2016).
  3. Prognostic Impact of Comorbidities in Hospitalized Patients with Acute Exacerbation of Chronic Heart Failure (EJIM – Scrutinio, et al., 2016).

Measuring Outcomes

  1. ACC/AHA/AACVPR/AAFP/ANA Concepts for Clinician-patient Shared Accountability in Performance Measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (JACC – Peterson, et al., 2014).
  2. Cardiovascular Health: The Importance of Measuring Patient-reported Health Status: A Scientific Statement from the American Heart Association (Circulation – Rumsfeld, et al., 2013).

Supplemental Bibliography

Sacubitril/Valsartan

  1. Comparing LCZ696 with Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores (JACC – Simpson et al., 2015)
  2. Efficacy and Safety of LCZ696 (Sacubitril-Valsartan) According to Age: Insights From PARADIGM-HF (EHJ – Jhund, et al., 2015).

Ivabradine

  1. Heart Rate Reduction with Ivabradine and Health Related Quality of Life in Patients with Chronic Heart Failure: Results from the SHIFT study (EHJ – Ekman, et al, 2011).
  2. Ivabradine in Heart Failure--No Paradigm SHIFT…yet (Lancet. Teerlink JR. 2010).

Prevention

  1. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging (JCHF – Bloom, et al., 2016).
  2. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions (JCHF – Hamo, et al., 2016).
  3. Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients with Breast Cancer Treated with Doxorubicin, Taxanes, and Trastuzumab (JACC – Ky, et al., 2014).
  4. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial (JAMA – Williamson, et al., 2016).
  5. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): a 2 × 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial of Candesartan and Metoprolol (EHJ – Gulati, et al., 2016).

Biomarkers/Monitors

  1. Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring (JACC HF – Costanzo, et al., 2016).
  2. Natriuretic Peptide-Based Screening and Collaborative Care for Heart Failure: The STOP-HF Randomized Trial (JAMA – Ledwidge, et al., 2013).
  3. PONTIAC (NT-proBNP Selected Prevention of Cardiac Events in a Population of Diabetic Patients Without a History of Cardiac Disease): A Prospective Randomized Controlled Trial (JACC – Huelsmann, et al., 2013).
  4. Rationale and Design of the GUIDE-IT Study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (JACC HF – Felker, et al., 2014).
  5. The Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide for Death and Cardiovascular Events in Healthy Normal and Stage A/B Heart Failure Subjects (JACC – McKie, et al., 2010).
  6. Use of Amino-Terminal Pro-B-Type Natriuretic Peptide to Guide Outpatient Therapy of Patients with Chronic Left Ventricular Systolic Dysfunction (JACC – Januzzi, et. al., 2011).

Comorbidities

  1. Co-morbidities in Patients with Heart Failure: An Analysis of the European Heart Failure Pilot Survey (EJHF - van Deursen, et al., 2013).

Presentations

  1. Allen. Session 1. What Does Care Optimization For HF Mean
  2. Butler. Session 3. Diabetes and Heart Failure
  3. Desai. Session 2. HFrEF. Sacubitril. Valsartan. Why, Who, When and How
  4. Fonarow. Session 1. Co-morbidities in HF - Defining a New Unmet Need
  5. Hernandez. Session 2. HFrEF. Ivabradine. Why, Who, When and How
  6. Januzzi. Session 1. How Might Biomarkers and Other Strategies Help Establish Adequacy of Care
  7. Jessup. Session 3. Cancer and Heart Failure. Avoiding LV Injury Stage a-B Patients
  8. Walsh. Opening Remarks
  9. Yancy. Session 2. What Do the New Guidelines Say
  10. Yancy. Session 3. Stop It Before It Happens